Trial Profile
A Randomised, Double-blind and Placebo-controlled Study Investigating the Pharmacodynamic Effects of Administration of Recombinant Human Factor VIII in Healthy Male Subjects Treated With the Monoclonal Anti-factor VIII Antibody, TB-402
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Factor VIII (Primary) ; TB 402 (Primary)
- Indications Venous thromboembolism
- Focus Pharmacodynamics
- Sponsors Oxurion; ThromboGenics
- 15 Apr 2014 New trial record